Healthcare focused asset manager, Lauxera Capital Partners, has closed its Growth Fund II at €400m, and is eyeing a final close of €500m by the end of the year, according to a release on its website. The most recent close follows its initial close in December 2024 at €300m.
In August of 2025, Tokyo-listed, Terumo, is a global medical device company originating from Japan, acquired Lauxera portfolio company OrganOx, a UK-based innovator in organ preservation devices, in a transaction valued at approximately US$1.5bn. It was one of the largest-ever deals in the UK medtech sector and one of the biggest spinouts from Oxford University.
In February 2022, Lauxera closed Growth I at more than €260m with funds dedicated to financing innovative HealthTech companies.